Life Briefing: Biotech Investors Urge Trump Amid M&A Activity Strategic angle: Smaller biotechs negotiate with the White House while addressing the trust gap in medicine. editorial-staff Apr 3
Life Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S. editorial-staff Apr 3
Life Briefing: Thursday was World Autism Awareness Day. HHS celebrated with…a workout? Strategic angle: Implications of SCOTUS' conversion therapy ruling, Trump hikes drug tariffs, and more Morning Rounds updates editorial-staff Apr 3
Life Briefing: Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine Strategic angle: “The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel. editorial-staff Apr 3
Life Briefing: Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs Strategic angle: Lenacapavir could put the end of the HIV epidemic in reach — if the people who need it can access it. Here’s one way to make that happen. editorial-staff Apr 3
Life Briefing: Supreme Court conversion therapy decision could ripple through medicine Strategic angle: A Supreme Court ruling this week on gender and sexuality 'conversion therapy' could narrow the authority of state medical boards over care involving speech. editorial-staff Apr 3
Life Supreme Court rules against Colorado ban on ‘conversion therapy’ for LGBTQ kids The Supreme Court's decision challenges state laws against a discredited practice aimed at LGBTQ+ youth. editorial-staff Apr 3
Life Briefing: Medicare Advantage plans win extra $18.6 billion as feds cut star ratings measures Strategic angle: CMS is scaling back the number of measures it uses to grade health insurers. editorial-staff Apr 2
Life Briefing: Small Drugmakers Negotiate Pricing Deals Amid Tariff Threat Strategic angle: The Trump administration is in talks with smaller pharmaceutical companies to establish new drug-pricing agreements. editorial-staff Apr 2
Life Briefing: Biotech investors’ plea to Trump, and a busy M&A week Strategic angle: How has the FDA's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? editorial-staff Apr 2
Life Briefing: FDA’s Evolving View of What Makes a ‘Breakthrough’ Device Strategic angle: An analysis of AI-powered devices that received the FDA's 'breakthrough' label. editorial-staff Apr 2
Life Briefing: How health care could gum up Trump’s reconciliation push Strategic angle: Cuts to health care spending might play a role in a complicated Congressional maneuver to fund immigration enforcement. editorial-staff Apr 2
Life Briefing: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds Strategic angle: Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout editorial-staff Apr 2
Life Briefing: Trump Administration Plans 100% Tariff on Patented Medicines Strategic angle: The FDA approves a new obesity pill from Lilly amidst tariff discussions. editorial-staff Apr 2
Life Briefing: A Preview of the Role Health Care May Play in the 2026 Election Strategic angle: Ahead of the 2026 midterm elections, this KFF issue brief examines the role health care has played in previous elections and its potential impact in 2026. editorial-staff Apr 2
Life Briefing: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts Strategic angle: A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment. editorial-staff Apr 2
Life Briefing: CDC Stops Testing for Rabies, Pox Viruses Strategic angle: When medical misinformation wins, testing an antidepressant for meth use, and other health news. editorial-staff Apr 2
Life Briefing: STAT+: ‘Takeover Tuesday’ saves biotech’s quarter Strategic angle: How 'Takeover Tuesday' saved biotech's first quarter. editorial-staff Apr 2
Life Briefing: Beyond detection: In the age of clinical AI, what counts as an FDA ‘breakthrough’ medical device? Strategic angle: An analysis of AI-powered devices that received FDA's 'breakthrough' label shows a preference for big-picture, multi-problem solutions. editorial-staff Apr 2
Life Briefing: Opinion: Medical misinformation wins when patients can’t see their doctors Strategic angle: Desperate patients, unable to get timely doctors’ appointments, seek help wherever they can find it. editorial-staff Apr 2